Pelthos Therapeutics, Inc. (PTHS)
10.26
+0.96
(+10.38%)
USD |
NYAM |
Nov 06, 09:59
Pelthos Therapeutics Debt to Equity Ratio : -48.71 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -48.71 |
| March 31, 2026 | 3.569 |
| December 31, 2025 | 0.8958 |
| September 30, 2025 | 0.0597 |
| June 30, 2025 | -0.5966 |
| March 31, 2025 | -0.5966 |
| September 30, 2024 | -1.602 |
| Date | Value |
|---|---|
| June 30, 2024 | -8.698 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | -0.1969 |
| September 30, 2023 | -0.2031 |
| June 30, 2023 | -0.2007 |
| March 31, 2023 | -0.1679 |
| December 31, 2022 | -0.1458 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Travere Therapeutics, Inc. | 27.28 |
| ACADIA Pharmaceuticals, Inc. | 0.0413 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 137.36M |
| Total Liabilities (Quarterly) | 138.86M |
| Shareholders Equity (Quarterly) | -1.501M |
| Current Ratio | 1.982 |
| Net Debt Paydown Yield | -13.44% |